» Articles » PMID: 16291718

Influence of Chronic Renal Failure on Stereoselective Metoprolol Metabolism in Hypertensive Patients

Overview
Publisher Wiley
Specialty Pharmacology
Date 2005 Nov 18
PMID 16291718
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The influence of chronic renal failure on the stereoselective metabolism of rac-metoprolol was investigated in 15 hypertensive patients, 7 of them with chronic renal failure and 8 with normal renal function. They were treated with rac-metoprolol (200 mg) for 7 days. The patients of both groups presented stereoselectivity in metoprolol metabolism, favoring the formation of 1'R-alpha-hydroxymetoprolol (AUC(1(')R/1(')S)(0-24) approximately 2.5) and (R)-metoprolol acidic metabolite (AUC((S)/(R))(0-24) = 0.8), the latter resulting in the plasma accumulation of (S)-metoprolol (AUC((S)/(R))(0-24) = 1.2). Patients with chronic renal failure presented plasma accumulation of the 4 alpha-hydroxymetoprolol isomers and of both metoprolol acidic metabolite enantiomers. A 50% reduction in Cl(R) does not explain the 3- to 4-fold plasma accumulation of metoprolol acidic metabolite in this group, suggesting that other pathways of metoprolol elimination are affected in chronic renal failure in addition to renal excretion. Chronic renal failure does not change the stereoselective kinetic disposition of metoprolol but modifies its stereoselective metabolism, inducing some of the CYP enzymes involved in the formation of the metoprolol acid metabolite.

Citing Articles

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.

Lee C, Kang P, Cho C, Park H, Lee Y, Bae J Arch Pharm Res. 2022; 45(6):433-445.

PMID: 35763157 DOI: 10.1007/s12272-022-01394-2.


A randomized, cross-over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence.

Mosley S, Kim S, El Rouby N, Lingineni K, Esteban V, Gong Y Clin Transl Sci. 2022; 15(7):1764-1775.

PMID: 35488487 PMC: 9283731. DOI: 10.1111/cts.13294.


Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Yoshida K, Sun B, Zhang L, Zhao P, Abernethy D, Nolin T Clin Pharmacol Ther. 2016; 100(1):75-87.

PMID: 26800425 PMC: 5024330. DOI: 10.1002/cpt.337.


Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.

Antunes N, Cavalli R, Marques M, Moises E, Lanchote V Br J Clin Pharmacol. 2014; 79(4):605-16.

PMID: 25291152 PMC: 4386945. DOI: 10.1111/bcp.12523.


Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Frank D, Jaehde U, Fuhr U Eur J Clin Pharmacol. 2007; 63(4):321-33.

PMID: 17273835 DOI: 10.1007/s00228-006-0250-8.